Report an error

Spotted something inaccurate in “Brain-Penetrant ROS1 Inhibitor Zidesamtinib Earns FDA Approval After Resistance Coverage Data”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.